TORONTO/MELBOURNE, August 1st, 2018
The Cell Care international cord blood banking group (“Cell Care”) – comprising Insception Lifebank and Cells for Life in Canada – today announced a strategic investment in ExCellThera Inc., a leading Montreal-based biotechnology company delivering molecules and bioengineering solutions to expand blood stem cells for therapeutic use.
The investment and associated collaboration between the companies is aimed at assisting ExCellThera to expand internationally more rapidly, support the supply of cord blood units, and further leverage ExCellThera’s expansion technologies into new therapeutic applications.
This initiative with ExCellThera continues Cell Care’s active investment in cord blood research programs. The company is already investing in cord blood clinical trials in regenerative medicine for type-1 diabetes and cerebral palsy.
“As Canada’s largest private cord blood bank, we are excited to have the opportunity to develop such a close association with one of Canada’s preeminent biotech businesses. This investment and strategic partnership fits well with our long-term goal to contribute to research that is advancing cord blood therapeutic options for patients globally.” said Mr. Brent Dennison, Cell Care Chief Executive Officer. “ExCellThera is a world leader in cord blood expansion, and we anticipate supporting its ongoing clinical research program and rapid growth plans into more therapeutic areas.”
“We are very pleased to have realised this collaboration with the Cell Care group,” said Dr. Guy Sauvageau, ExCellThera President and Chief Executive Officer. “Cell Care brings international clinical trial experience and business development capability, and we look forward to leveraging the synergies between our two companies to accelerate our strategy.”
About ExCellThera Inc.
ExCellThera is a biotechnology company delivering molecules and bioengineering solutions to expand blood stem cells for therapeutic use. ExCellThera’s lead technology, ECT-001, combines a proprietary small molecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its portfolio of products, as well as supporting best-in-class clinical trials. www.excellthera.com
About the Cell Care group
The Cell Care group comprises Cell Care in Australia and Insception–Biosciences, Cells for Life and the Victoria Angel public bank in Canada. The combined group is one of the world’s top 10 companies in the sector with over 150,000 cord blood and tissue samples stored. Cell Care has invested in Australian clinical trials investigating the impact of autologous cord blood in type-1 diabetes, sibling cord blood in cerebral palsy and has supported research into expansion technologies for a number of years. Visit www.insception.com for more information
For further information:
Media relations, ExCellThera